{
    "url_original": "https://www.wsj.com/articles/glaxosmithkline-racing-to-provide-only-effective-covid-19-antibody-treatment-11642770001?mod=business_lead_pos3",
    "url": "glaxosmithkline-racing-to-provide-only-effective-covid-19-antibody-treatment-11642770001",
    "title": "GlaxoSmithKline Racing to Provide Only Effective Covid-19 Antibody Treatment",
    "sub_head": "GlaxoSmithKline and Vir Biotechnology are increasing output at a second plant to help meet demand for sotrovimab",
    "category_1": "Health",
    "time": "2022-01-21 08:00:00",
    "body": "GlaxoSmithKline  PLC and partner  Vir Biotechnology Inc.  are straining to meet soaring demand for their Covid-19 antibody treatment after the highly mutated Omicron variant knocked out the two competing products.<br />Demand has jumped in recent weeks for the treatment, called sotrovimab, because it is the only antibody drug authorized in the U.S. for the newly infected that has been found to work against Omicron."
}